
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics Inc. has demonstrated significant efficacy of its product candidate, lorundrostat, in reducing blood pressure, achieving a robust placebo-adjusted reduction of 9.1 mmHg at six weeks and 11.7 mmHg at twelve weeks in clinical trials. The positive safety profile, including a low incidence of hyperkalemia at 1.1%, and the potential for daily use in patients with uncontrolled and resistant hypertension, enhance the attractiveness of lorundrostat as a viable treatment option. This combination of strong clinical outcomes and the ability to offer a differentiated mechanism of action positions Mineralys favorably for future growth and development within the biopharmaceutical market.
Bears say
Mineralys Therapeutics Inc reported a net loss of $48.9 million for the fourth quarter of 2024, and a total net loss of $177.8 million for the full year, translating to losses of $0.98 and $3.66 per share, respectively. The company faces significant risks, including the potential failure of its product candidate, lorundrostat, to meet peak commercial revenue estimates, which may stem from limitations related to market size, penetration rates, and pricing strategies. Additionally, the company's ability to secure necessary capital resources for ongoing operations and program development poses a critical challenge to its financial stability and long-term viability.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares